Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine-Reference-Cited by-同舟云学术

Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine

Published:2022-02-22 Issue:1 Volume:13 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Furuyama Wakako¹,Shifflett Kyle¹,Pinski Amanda N.²,Griffin Amanda J.¹,Feldmann Friederike³,Okumura Atsushi¹^ORCID,Gourdine Tylisha¹,Jankeel Allen²,Lovaglio Jamie³,Hanley Patrick W.³,Thomas Tina³,Clancy Chad S.³,Messaoudi Ilhem²^ORCID,O’Donnell Kyle L.¹,Marzi Andrea¹^ORCID

Affiliation:

1. Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA

2. Department of Molecular Biology and Biochemistry, University of California—Irvine, Irvine, California, USA

3. Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA

Abstract

The vesicular stomatitis virus (VSV) vaccine platform rose to fame in 2019, when a VSV-based Ebola virus (EBOV) vaccine was approved by the European Medicines Agency and the U.S. Food and Drug Administration for human use against the deadly disease.

Funder

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

HHS | NIH | National Center for Research Resources

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mbio.03379-21

Reference60 articles.

1. A pneumonia outbreak associated with a new coronavirus of probable bat origin

2. Clinical Characteristics of Coronavirus Disease 2019 in China